CN112385733B - 一种低致敏大豆蛋白粉及其制备方法 - Google Patents
一种低致敏大豆蛋白粉及其制备方法 Download PDFInfo
- Publication number
- CN112385733B CN112385733B CN202011152976.2A CN202011152976A CN112385733B CN 112385733 B CN112385733 B CN 112385733B CN 202011152976 A CN202011152976 A CN 202011152976A CN 112385733 B CN112385733 B CN 112385733B
- Authority
- CN
- China
- Prior art keywords
- soybean protein
- hypoallergenic
- solution
- powder
- polyphenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010073771 Soybean Proteins Proteins 0.000 title claims abstract description 92
- 235000019710 soybean protein Nutrition 0.000 title claims abstract description 60
- 239000000843 powder Substances 0.000 title claims abstract description 58
- 230000000774 hypoallergenic effect Effects 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 26
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 23
- 235000018102 proteins Nutrition 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 239000000376 reactant Substances 0.000 claims abstract description 16
- 235000000346 sugar Nutrition 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 238000004108 freeze drying Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940001941 soy protein Drugs 0.000 claims description 33
- 229940074393 chlorogenic acid Drugs 0.000 claims description 9
- 229950001002 cianidanol Drugs 0.000 claims description 9
- 229940016667 resveratrol Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 7
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 7
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 7
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 7
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 7
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 7
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000005487 catechin Nutrition 0.000 claims description 7
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 7
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 7
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 7
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 235000021283 resveratrol Nutrition 0.000 claims description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 5
- 235000001785 ferulic acid Nutrition 0.000 claims description 5
- 229940114124 ferulic acid Drugs 0.000 claims description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 5
- 101710102211 11S globulin Proteins 0.000 claims description 3
- 101000767750 Carya illinoinensis Vicilin Car i 2.0101 Proteins 0.000 claims description 3
- 101000767759 Corylus avellana Vicilin Cor a 11.0101 Proteins 0.000 claims description 3
- 101710190853 Cruciferin Proteins 0.000 claims description 3
- 101000622316 Juglans regia Vicilin Jug r 2.0101 Proteins 0.000 claims description 3
- 101000767757 Pinus koraiensis Vicilin Pin k 2.0101 Proteins 0.000 claims description 3
- 101000767758 Pistacia vera Vicilin Pis v 3.0101 Proteins 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims 1
- 229920002414 procyanidin Polymers 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 21
- 108010005094 Advanced Glycation End Products Proteins 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 13
- 206010070834 Sensitisation Diseases 0.000 abstract description 12
- 230000008313 sensitization Effects 0.000 abstract description 12
- 230000002411 adverse Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 38
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 13
- 235000010469 Glycine max Nutrition 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 229940071440 soy protein isolate Drugs 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
- A23J3/16—Vegetable proteins from soybean
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及一种低致敏大豆蛋白粉及其制备方法,该方法包括:向大豆蛋白水溶液中加入食源多酚,搅拌均匀,调溶液的pH至碱性,置于室温暗处反应24h,得到多酚‑大豆蛋白共价复合物溶液;向所述多酚‑大豆蛋白共价复合物溶液中加入低聚还原糖,搅拌均匀,得到反应溶液;将所述反应溶液冷冻干燥,得到反应物粉末;将所述反应物粉末置于温度55~65℃、相对湿度75%条件下反应12~36h,得到低致敏大豆蛋白粉。从而可在降低大豆蛋白致敏性的同时,最大限度地减少其中的晚期糖基化终末产物,避免了伴随产物对人体健康的不良影响。
Description
技术领域
本发明涉及水食品加工领域,具体涉及一种低致敏大豆蛋白粉及其方法。
背景技术
大豆蛋白具有营养价值高、易制备、来源广、成本低等特点,是为数不多的可用于替代动物蛋白的植物蛋白种类,已成为食品加工领域重要的原料之一。但是,大豆是联合国粮农组织公认的八大类易致敏食物之一,大豆过敏在非特定及特定人群中的发病率约为0.27%~1.9%,其中在婴幼儿中的发病率约为0.4%,临床症状有鼻炎、皮疹、哮喘和胃肠道不适等,严重时可影响其健康成长和发育。随着国民经济和食品工业的快速发展,大豆蛋白在婴幼儿食品等领域的应用不断扩展,大豆过敏的发病率呈不断上升趋势。因此,降低大豆蛋白的致敏性具有十分重要的现实意义和广阔的市场前景。
糖基化是常用于降低大豆蛋白致敏性的方法,其原理是采用还原糖与蛋白质之间的非酶褐变反应(美拉德反应)诱导多肽链发生交联和侧链接枝,改变蛋白构象结构,进而破坏其抗原表位,制得低致敏性大豆蛋白产物。然而,美拉德反应较难控制,进入中期反应阶段后生成的晚期糖基化终末产物(AGEs)被证明与人体老化、糖尿病、慢性肾病、心脑血管疾病等慢性非传染性疾病密切相关,这为糖修饰低敏蛋白制品的应用带来了潜在隐患。
发明内容
本发明旨在至少在一定程度上解决相关技术中的技术问题之一。为此,本发明的目的在于提供一种低致敏大豆蛋白粉的制备方法。该方法可在降低大豆蛋白致敏性的同时,最大限度地减少其中的晚期糖基化终末产物,避免了伴随产物对人体健康的不良影响。
为此,在本发明的一方面,本发明提出了一种低致敏大豆蛋白粉的制备方法,包括以下步骤:
向大豆蛋白水溶液中加入食源多酚,搅拌均匀,调溶液的pH至碱性,置于室温暗处反应24h,得到多酚-大豆蛋白共价复合物溶液;
向所述多酚-大豆蛋白共价复合物溶液中加入低聚还原糖,搅拌均匀,得到反应溶液;
将所述反应溶液冷冻干燥,得到反应物粉末;
将所述反应物粉末置于温度55~65℃、相对湿度75%条件下反应12~36h,得到低致敏大豆蛋白粉。
根据本发明实施例的低致敏大豆蛋白粉的制备方法,利用在碱性条件下,多酚可通过自氧化作用与蛋白质发生共价交联,改变蛋白质构象结构和有关物化特性,且形成的多酚-致敏蛋白复合物具有较强的抗氧化性和潜在的低致敏性;相较单糖而言,低聚糖和多糖在糖基化体系中由于空间位阻效应生成的AGEs含量较低,且制得的糖基化蛋白特性优良,无不良感官风味;由此,通过多酚共价修饰联合干热法糖基化反应使多肽链发生交联和侧链接枝,破坏大豆蛋白致敏原的表位结构,同时利用多酚及其醌类中间体的抗氧化作用及低聚糖/多糖的空间位阻作用,降低体系生成的晚期糖基化终末产物及其前体,从而使本申请制得的糖修饰低敏大豆蛋白粉,在保有糖基化产物低致敏性的同时,最大限度地减少了其中的晚期糖基化终末产物,避免了其对健康的不利影响。该方法操作简便、起效快,改良效果显著;同时,制备的大豆分离蛋白粉风味优良、安全性和稳定性好,易实现产业化生产。
另外,根据本发明上述实施例提出的低致敏大豆蛋白粉的制备方法,还可以具有如下附加的技术特征:
可选地,溶液的pH调至9.0。
可选地,大豆蛋白为大豆浓缩蛋白、大豆分离蛋白、7S球蛋白和11S球蛋白中的任意一种。
可选地,所述食源多酚为绿原酸、阿魏酸、白藜芦醇、儿茶素、原花青素中的任意一种或几种的混合。
可选地,所述食源多酚为绿原酸提取物、阿魏酸提取物、白藜芦醇提取物、儿茶素提取物、原花青素提取物中的任意一种或几种的混合。
可选地,所述低聚还原糖为低聚半乳糖、甘露寡糖、寡壳糖和葡聚糖中的任意一种或几种的混合。
可选地,所述食源多酚的加入量为25~100μmol/g的大豆蛋白。
可选地,所述低聚还原糖与大豆蛋白质量比为1:1~4:1。
可选地,所述冷冻干燥为于-20℃冰箱内预冻24h后,于-40~-50℃下冷冻干燥16~24h。
本发明在另一方面提出了一种低致敏大豆蛋白粉,其采用上述的低致敏大豆蛋白粉的制备方法制得。
根据本发明的一种低致敏大豆蛋白粉,其通过上述方法可制备出兼具低致敏性和低水平晚期糖基化终末产物的大豆蛋白粉。
本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。
附图说明
图1为根据本发明实施例中低致敏大豆蛋白的荧光性AGEs含量;
图2为根据本发明实施例中低致敏大豆蛋白的CML含量;
图3为根据本发明实施例的低致敏大豆蛋白的IgE结合能力。
具体实施方式
以下通过特定的具体实例说明本发明的技术方案。应理解,本发明提到的一个或多个方法步骤并不排斥在所述组合步骤前后还存在其他方法步骤或在这些明确提到的步骤之间还可以插入其他方法步骤;还应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。而且,除非另有说明,各方法步骤的编号仅为鉴别各方法步骤的便利工具,而非为限制各方法步骤的排列次序或限定本发明可实施的范围,其相对关系的改变或调整,在无实质变更技术内容的情况下,当亦视为本发明可实施的范畴。
为了更好的理解上述技术方案,下面更详细地描述本发明的示例性实施例。虽然显示了本发明的示例性实施例,然而应当理解,可以以各种形式实现本发明而不应被这里阐述的实施例所限制。相反,提供这些实施例是为了能够更透彻地理解本发明,并且能够将本发明的范围完整的传达给本领域的技术人员。
本发明采用的试材皆为普通市售品,皆可于市场购得。
本发明的室温均为25℃。
根据本发明的实施例,本发明提出了一种低敏大豆蛋白粉的制备方法,其包括以下步骤(优选条件):
(1)向大豆蛋白水溶液中加入食源多酚,搅拌均匀,调溶液的pH至碱性,置于室温暗处反应24h,得到多酚-大豆蛋白共价复合物溶液。根据本发明的具体实施例,可以是将大豆蛋白以50mg/mL的浓度分散于蒸馏水中,加入25~100μmol/g的食源多酚,搅拌至充分溶解,用2mol/L NaOH将体系pH调至9.0,而后室温暴露于空气中暗处反应24h,得到共价复合物溶液。其中,食源多酚可以是绿原酸、阿魏酸、白藜芦醇、儿茶素、原花青素中的任意一种或几种的混合。或者,食源多酚可以是绿原酸提取物、阿魏酸提取物、白藜芦醇提取物、儿茶素提取物、原花青素提取物中的任意一种或几种的混合。其中,大豆蛋白可以是大豆浓缩蛋白、大豆分离蛋白、7S球蛋白和11S球蛋白中的任意一种。
(2)向所述多酚-大豆蛋白共价复合物溶液中加入与大豆蛋白质量比为1:1~4:1的低聚还原糖,于室温搅拌均匀后得到反应溶液。根据本发明的具体实施例,可以是向所述的共价复合物溶液中加入寡壳糖,添加量为与加入大豆分离蛋白粉的质量的4倍。其中,所述低聚还原糖可以是低聚半乳糖、甘露寡糖、寡壳糖和葡聚糖中的任意一种或几种的混合。
(3)将所得的反应溶液置于-20℃条件下冷却,冷冻干燥后,得到反应物粉末。根据本发明的具体实施例,可以是将反应后溶液立即置于-20℃冰箱内,预冻24h后于-40~-50℃冷冻干燥16~24h,得到反应物粉末。
(4)将所述反应物粉末在温度55~65℃,相对湿度75%条件下反应12~36h,得到低致敏大豆蛋白粉。根据本发明的具体实施例,可以是将反应物粉末进行干法糖基化,条件可设为:温度60℃,湿度75%,反应时间36h。
由此,通过多酚共价修饰结合干热法糖基化反应破坏大豆蛋白中致敏原的表位结构,同时利用多酚及其醌类中间体的抗氧化能力及低聚糖/多糖的空间位阻作用,靶向降低体系中晚期糖基化终末产物的生成,在维持糖修饰蛋白低致敏性的同时,极大限度地降低了其中对人体健康有不良影响的伴随产物;经过本发明方法制备的低致敏大豆蛋白粉的致敏性下降了45.7~61.3%,同时其中荧光性晚期糖基化终末产物的含量降低了58.9~70.3%,羧甲基赖氨酸的含量降低了39.7~50.5%。该方法操作便捷,稳定性好,易实现产业化生产,产品品质和安全性好。
下面参考具体实施例,对本发明进行描述,需要说明的是,这些实施例仅仅是描述性的,而不以任何方式限制本发明。
实施例1
(1)取大豆分离蛋白粉5000mg,1772mg绿原酸(相当于100μmol/g大豆蛋白),加蒸馏水100mL,于室温下搅拌2h以充分溶解,用2mol/L NaOH将溶液pH调至9.0,而后将溶液于室温并暴露于空气中暗处反应24h,得到大豆蛋白-绿原酸共价复合物溶液。
(2)向步骤(1)的大豆蛋白-绿原酸共价复合物溶液中加入20000mg的寡壳糖,使大豆蛋白:寡壳糖质量比为1:4,持续搅拌30min,得到反应溶液。
(3)将步骤(2)的反应溶液置于-20℃冰箱中冷却并预冻24h后,于-45℃下冷冻干燥24h,得到反应物粉末。
(4)将步骤(3)的反应物粉末置于温度60℃,湿度75%条件下反应36h,得到糖修饰产物固体粉末。
(5)将步骤(4)的糖修饰产物固体粉末研磨过100目筛,得到低致敏大豆蛋白粉。
实施例2
(1)取大豆分离蛋白粉5000mg,36mg儿茶素(相当于25μmol/g大豆蛋白),加蒸馏水100mL,于室温下搅拌2h以充分溶解,用2mol/L NaOH将溶液pH调至9.0,而后将溶液于室温并暴露于空气中暗处反应24h,得到大豆蛋白-儿茶素共价复合物溶液。
(2)向步骤(1)的大豆蛋白-儿茶素共价复合物溶液中加入5000mg的低聚半乳糖,使大豆蛋白:低聚半乳糖质量比为1:1,持续搅拌30min,得到反应溶液。
(3)将步骤(2)的反应溶液置于-20℃冰箱中冷却并预冻24h后,于-45℃下冷冻干燥24h,得到反应物粉末。
(4)将步骤(3)的反应物粉末置于温度55℃,湿度75%条件下反应12h,得到糖修饰产物固体粉末。
(5)将步骤(4)的糖修饰产物固体粉末研磨过100目筛,得到低致敏大豆蛋白粉。
实施例3
(1)取大豆分离蛋白粉5000mg,57mg白藜芦醇(相当于50μmol/g大豆蛋白),加蒸馏水100mL,于室温下搅拌2h以充分溶解,用2mol/L NaOH将溶液pH调至9.0,而后将溶液于室温并暴露于空气中暗处反应24h,得到大豆蛋白-白藜芦醇共价复合物溶液。
(2)向步骤(1)的大豆蛋白-白藜芦醇共价复合物溶液中加入10000mg的葡聚糖(分子量为10kDa),使大豆蛋白:葡聚糖质量比为1:2,持续搅拌30min,得到反应溶液。
(3)将步骤(2)的反应溶液置于-20℃冰箱中冷却并预冻24h后,于-45℃下冷冻干燥24h,得到反应物粉末。
(4)将步骤(3)的反应物粉末置于温度65℃,湿度75%条件下反应24h,得到糖修饰产物固体粉末。
(5)将步骤(4)的糖修饰产物固体粉末研磨过100目筛,得到低致敏大豆蛋白粉。
对比例1
对比例1与实施例1的不同之处在于:采用葡萄糖代替寡壳糖,且不添加绿原酸。其他均与实施例1相同。
对比例2
对比例2与实施例2的不同之处在于:采用果糖代替低聚半乳糖,且不添加儿茶素。其他均与实施例1相同。
对比例3
对比例3与实施例3的不同之处在于:采用核糖代替葡聚糖,且不添加白藜芦醇。其他均与实施例3相同。
试验例
以实施例1~3和对比例1~3制备得到的低致敏大豆蛋白粉为试验样品,进行大豆分离蛋白的性能测试。
1、荧光性晚期糖基化终末产物含量检测
将浓度为5mg/mL的试验样品溶液置于荧光分光光度计中,于激发波长350nm,发射波长440nm处测定其荧光强度。
晚期糖基化终末产物含量(%)=F样品/F对照×100%,其中,F样品和F对照分别为样品组(含低聚还原糖和食源多酚)和对照组(仅有低聚还原糖,无食源多酚)的荧光强度。
结果如图1所示,实施例1~3的糖修饰低敏大豆蛋白的荧光性晚期糖基化终末产物含量均较对应的对比例显著降低;其中实施例1的糖修饰低敏大豆蛋白的荧光性晚期糖基化终末产物含量为相应对照组的29.7%。实施例2的糖修饰低敏大豆蛋白的荧光性晚期糖基化终末产物含量为相应对照组的41.1%。实施例3的糖修饰低敏大豆蛋白的荧光性晚期糖基化终末产物含量为相应对照组的31.6%。
2、羧甲基赖氨酸生成量检测
利用市售的羧甲基赖氨酸(CML)ELISA试剂盒检测实施例1~3和对比例1~3获得的糖修饰低敏大豆蛋白溶液中的CML含量。
CML生成含量(%)=C样品/C对照×100%,其中,C样品和C对照分别为样品组(含低聚还原糖和食源多酚)和对照组(仅有低聚还原糖,无食源多酚)的CML含量。
结果如图1所示,实施例1~3的糖修饰低敏大豆蛋白的CML含量均较对应的对比例显著降低;实施例1的糖修饰低敏大豆蛋白的CML含量为相应对照组的49.5%。实施例2的糖修饰低敏大豆蛋白的CML含量为相应对照组的60.3%。实施例3的糖修饰低敏大豆蛋白的CML含量为相应对照组的51.3%。
3、大豆蛋白致敏性检测
通过间接ELISA法检测大豆蛋白的IgE的结合能力以反映大豆蛋白致敏性变化:
分别将浓度为500μg/mL的实施例1~3获得的糖修饰低敏大豆蛋白溶液加到酶标板上,每孔加0.1mL,以未处理的大豆蛋白溶液作为对照。4℃过夜。洗涤液洗板5次,每次250μL/孔,室温孵育5min,拍干。每孔加200μL含5%的牛血清蛋白封闭,于37℃孵育2h,洗板5次;加入1:30稀释的大豆过敏患者混合血清100μL/孔,于37℃孵育1h,反应结束后,洗板5次;加入1:5000稀释的生物素标记羊抗人IgE 200μL/孔,37℃孵育2h,洗板5次;加入TMB100μL/孔,于37℃避光显色30min;显色后加入2mol/L H2SO4 50μL/孔终止反应,并于波长450nm处测定其吸光值(OD值)。
IgE结合能力(%)=OD样品/OD对照×100%,其中,OD样品和OD对照分别为样品组(含低聚还原糖和食源多酚)和对照组(未处理蛋白)的OD值。
所得数据采用IBM SPSS Statistics 22.0软件对数据进行统计和分析,p<0.05表示有显著性差异。图形绘制使用GraphPad Prism 8。
结果如图3所示,实施例1的糖修饰低敏大豆蛋白的致敏性较未处理的大豆蛋白下降了61.3%。实施例2的糖修饰低敏大豆蛋白的致敏性较未处理的大豆蛋白下降了45.7%。实施例3的糖修饰低敏大豆蛋白的致敏性较未处理的大豆蛋白下降了56.7%。在各实施例中,食源多酚的加入并未显著改变糖修饰降低大豆蛋白致敏性的效果,说明形成了可改变抗原表位的糖基化位点,多酚-致敏蛋白复合靶向遏制了生成糖基化终末产物的进程,但并未影响产物的致敏特性。
由此可知,本发明利用食源多酚共价修饰联合干热法糖基化反应破坏大豆蛋白中致敏原的表位结构,结合多酚及其醌类中间体的抗氧化能力及低聚糖/多糖的空间位阻作用抑制晚期糖基化终末产物的生成,很大程度地降低了体系中晚期糖基化终末产物的含量,在保持糖修饰产物低致敏性的同时,大幅度地降低了其中对人体健康有不良影响的内源性伴随产物;经过本发明方法制备的糖修饰低敏大豆蛋白粉致敏性下降了45.7~61.3%,同时其中荧光性晚期糖基化终末产物的含量降低了58.9~70.3%,羧甲基赖氨酸的含量降低了39.7~50.5%。该方法操作便捷,起效快,稳定性好,易实现产业化生产,产品品质和安全性好。
在本说明书的描述中,参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不应理解为必须针对的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。此外,本领域的技术人员可以将本说明书中描述的不同实施例或示例进行接合和组合。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (6)
1.一种低致敏大豆蛋白粉的制备方法,其特征在于,包括以下步骤:
向大豆蛋白水溶液中加入食源多酚,搅拌均匀,调溶液的pH至9.0,置于室温暗处反应24 h,得到多酚-大豆蛋白共价复合物溶液;所述食源多酚的加入量为25~100 μmol/g的大豆蛋白;
向所述多酚-大豆蛋白共价复合物溶液中加入低聚还原糖,搅拌均匀,得到反应溶液;所述低聚还原糖与大豆蛋白质量比为1:1~4:1;
将所述反应溶液冷冻干燥,得到反应物粉末;
将所述反应物粉末置于温度55~65℃、相对湿度75%条件下反应12~36 h,得到低致敏大豆蛋白粉。
2.如权利要求1所述的低致敏大豆蛋白粉的制备方法,其特征在于,大豆蛋白为大豆浓缩蛋白、大豆分离蛋白、7S球蛋白和11S球蛋白中的任意一种。
3.如权利要求1所述的低致敏大豆蛋白粉的制备方法,其特征在于,所述食源多酚为绿原酸、阿魏酸、白藜芦醇、儿茶素、原花青素中的任意一种或几种的混合。
4.如权利要求1所述的低致敏大豆蛋白粉的制备方法,其特征在于,所述低聚还原糖为低聚半乳糖、甘露寡糖、寡壳糖中的任意一种或几种的混合。
5.如权利要求1所述的低致敏大豆蛋白粉的制备方法,其特征在于,所述冷冻干燥为于-20 ℃冰箱内预冻24 h后,于-40~-50 ℃下冷冻干燥16~24 h。
6.一种采用如权利要求1-5中任一项所述的低致敏大豆蛋白粉的制备方法制得的低致敏大豆蛋白粉。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011152976.2A CN112385733B (zh) | 2020-10-26 | 2020-10-26 | 一种低致敏大豆蛋白粉及其制备方法 |
NL2029200A NL2029200B1 (en) | 2020-10-26 | 2021-09-17 | Gluten-free hypoallergenic soy protein flour and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011152976.2A CN112385733B (zh) | 2020-10-26 | 2020-10-26 | 一种低致敏大豆蛋白粉及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112385733A CN112385733A (zh) | 2021-02-23 |
CN112385733B true CN112385733B (zh) | 2023-11-17 |
Family
ID=74596156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011152976.2A Active CN112385733B (zh) | 2020-10-26 | 2020-10-26 | 一种低致敏大豆蛋白粉及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112385733B (zh) |
NL (1) | NL2029200B1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116210803A (zh) * | 2023-02-06 | 2023-06-06 | 东北农业大学 | 一种与多酚复合提高大豆分离蛋白稳定性的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002068991A (ja) * | 2000-08-31 | 2002-03-08 | Kanji Ishimaru | ポリフェノールータンパク複合体の調製法、および得られた複合体 |
CN104686809A (zh) * | 2015-03-26 | 2015-06-10 | 石河子大学 | 一种甘草多糖-大豆分离蛋白偶合物及其制备方法和应用 |
CN108719999A (zh) * | 2018-05-07 | 2018-11-02 | 中国农业大学 | 一种蛋白质-多酚-多糖共价复合物的制备方法及其应用 |
CN109123067A (zh) * | 2018-09-29 | 2019-01-04 | 深圳大学 | 一种降低牛乳蛋白致敏性的方法及低致敏牛乳蛋白 |
CN111084388A (zh) * | 2019-12-12 | 2020-05-01 | 浙江李子园食品股份有限公司 | 一种低致敏乳蛋白粉及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2254425A1 (en) * | 2008-03-19 | 2010-12-01 | Wisconsin Alumni Research Foundation | Production of protein-polysaccharide conjugates |
US20150173406A1 (en) * | 2012-07-09 | 2015-06-25 | North Carolina State University | Hypoallergenic food-grade protein matrices and uses thereof |
CN106455625B (zh) * | 2015-04-30 | 2020-02-07 | 中国食品发酵工业研究院 | 一种低致敏低苦味大豆低聚肽及其制备方法和应用 |
-
2020
- 2020-10-26 CN CN202011152976.2A patent/CN112385733B/zh active Active
-
2021
- 2021-09-17 NL NL2029200A patent/NL2029200B1/en active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002068991A (ja) * | 2000-08-31 | 2002-03-08 | Kanji Ishimaru | ポリフェノールータンパク複合体の調製法、および得られた複合体 |
CN104686809A (zh) * | 2015-03-26 | 2015-06-10 | 石河子大学 | 一种甘草多糖-大豆分离蛋白偶合物及其制备方法和应用 |
CN108719999A (zh) * | 2018-05-07 | 2018-11-02 | 中国农业大学 | 一种蛋白质-多酚-多糖共价复合物的制备方法及其应用 |
CN109123067A (zh) * | 2018-09-29 | 2019-01-04 | 深圳大学 | 一种降低牛乳蛋白致敏性的方法及低致敏牛乳蛋白 |
CN111084388A (zh) * | 2019-12-12 | 2020-05-01 | 浙江李子园食品股份有限公司 | 一种低致敏乳蛋白粉及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Si-Duo Zhou 等.Soy protein isolate -(-)-epigallocatechin gallate conjugate: Covalent binding sites identification and IgE binding ability evaluation.Food Chemistry.2020,第333卷1-8. * |
张驰 等.植物多酚与花生致敏蛋白相互作用及脱敏机理研究进展.食品科学.2019,第40卷(第23期),313-318. * |
Also Published As
Publication number | Publication date |
---|---|
NL2029200B1 (en) | 2022-06-24 |
NL2029200A (en) | 2022-06-16 |
CN112385733A (zh) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
He et al. | Function, digestibility and allergenicity assessment of ovalbumin–EGCG conjugates | |
He et al. | Covalent conjugation with (−)-epigallo-catechin 3-gallate and chlorogenic acid changes allergenicity and functional properties of Ara h1 from peanut | |
Maleki et al. | The effects of roasting on the allergenic properties of peanut proteins | |
CN112385733B (zh) | 一种低致敏大豆蛋白粉及其制备方法 | |
Lei et al. | The effect of deamidation on the structural, functional, and rheological properties of glutelin prepared from Akebia trifoliata var. australis seed | |
Xu et al. | Effect of deacetylated konjac glucomannan on heat-induced structural changes and flavor binding ability of fish myosin | |
Yu-Tong et al. | Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion | |
Morales‐de León et al. | Preparation and characterization of protein isolate from fresh and hardened beans (Phaseolus vulgaris L.) | |
Mihajlovic et al. | Peanut protein structure, polyphenol content and immune response to peanut proteins in vivo are modulated by laccase | |
Zhang et al. | Effect of d-galactose on physicochemical and functional properties of soy protein isolate during Maillard reaction | |
Ayala-Rodríguez et al. | Nutritional quality of protein flours of fava bean (Vicia faba L.) and in vitro digestibility and bioaccesibility | |
Tao et al. | Improving the antioxidant activity, in vitro digestibility and reducing the allergenicity of whey protein isolate by glycosylation with short-chain inulin and interaction with cyanidin-3-glucoside | |
US20070092632A1 (en) | Ultra high pressure modified proteins and uses thereof | |
Rudeschko et al. | Optimization of apple allergen preparation for in vivo and in vitro diagnostics | |
Boonlao et al. | Glycation of soy protein isolate with maltodextrin through Maillard reaction via dry and wet treatments and compare their techno-functional properties | |
CN111084388A (zh) | 一种低致敏乳蛋白粉及其制备方法 | |
CN112641103B (zh) | 一种含有牡蛎肽的复合蛋白粉及其制备方法 | |
JPH022392A (ja) | タンパク質水解物の製法 | |
Sharma et al. | Manipulation of protein structure and bonding pattern to improve the gelling and textural quality of surimi gels from silver carp: incorporation of mosambi (Citrus limetta) peel extract | |
Yu et al. | High intensity ultrasound-assisted quality enhancing of the marinated egg: Gel properties and in vitro digestion analysis | |
Yang et al. | Changes in the structural and physicochemical properties of wheat gliadin and maize amylopectin conjugates induced by dry‐heating | |
Namlı | Microwave glycation of soy protein isolate | |
CN112021408B (zh) | 一种改善奶粉致敏性的加工方法 | |
WO2020134772A1 (zh) | 一种含有糖醇的β - 乳球蛋白 - 维生素结合物及其制备方法 | |
Qie et al. | Interaction between β-casein and phlorizin induced by thermal treatment and its effect on the antioxidant activity and bioavailability of phlorizin in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |